Loading
People with HIV whose lymphoma had relapsed did as well after high-dose chemotherapy and a stem cell transplant as matched HIV-negative patients, with 87 percent alive at one year.
Single-arm phase 2 trial of the Blood and Marrow Transplant Clinical Trials Network and AIDS Malignancy Consortium: 43 HIV-infected patients with chemotherapy-sensitive relapsed or persistent aggressive B-cell or Hodgkin lymphoma were enrolled and 40 underwent autologous transplant after BEAM conditioning with consistent peri-transplant antiretroviral management.
At a median follow-up of 24.8 months one- and two-year overall survival were 87.3 and 82 percent, two-year progression-free survival 79.8 percent and one-year transplant-related mortality 5.2 percent; neutrophil and platelet recovery took 11 and 18 days; outcomes did not differ from 151 matched registry controls.
HIV infection is not a reason to withhold autologous transplant from patients with relapsed lymphoma who meet standard transplant criteria.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/